Lineage Cell Therapeutics

Lineage Cell Therapeutics

Lineage Cell Therapeutics was formed in 2013 through the merger of BioTime and Asterias Biotherapeutics, with Brian Culley serving as CEO. The publicly traded company, listed on the NYSE American, operates in the regenerative medicine space rather than as a traditional investment firm. Its core technology platform centers on pluripotent stem cells, which the company differentiates into specific cell types for therapeutic transplantation. The company's clinical pipeline is focused on ophthalmology, neurology, and oncology. Its lead candidate, OpRegen, is a retinal pigment epithelium cell therapy for dry age-related macular degeneration, partnered with Roche's Genentech unit. A second program, OPC1, involves oligodendrocyte progenitor cells for spinal cord injury. A third, VAC2, is a dendritic cell vaccine for solid tumors. The geographic focus for clinical testing includes the United States and Europe, reflecting the regulatory pathways for advanced therapy medicinal products. Lineage operates from Carlsbad, California and employs a lean team of scientists and business-development professionals. The company does not report assets under management in the style of a fund; instead, its resources are measured by market capitalization, cash reserves, and partnership milestones. In December 2021, Genentech exercised its option to acquire OpRegen, generating a $50 million milestone payment for Lineage. The company also maintains a cell-therapy manufacturing facility in Israel, acquired through earlier corporate transactions. What distinguishes Lineage's capital approach is its dual model of value realization: it does not take management fees but instead funds development through equity raises and strategic partnerships. The Genentech deal in ophthalmology created a path where a larger pharmaceutical partner funds late-stage trials and commercialization, while Lineage focuses on early clinical work. This hybrid operating company-developer structure allows it to behave as both a drug developer and a royalty-like asset holder.